A slew of major companies are reporting earnings this week. Healthcare giant Johnson & Johnson (JNJ) will announce fourth-quarter earnings on Tuesday before the bell. Analysts expect earnings to climb 12.10% to $1.95 per share while revenue will decline by 0.10% to $20.17 billion. The top line is likely to be hurt by the slower growth pace in the Pharmaceuticals segment as biosimilar and generic competition could pressure the segment.
Energy exploration firm Halliburton (HAL) will report fourth-quarter results on Tuesday. Analysts predict earnings of $0.37 per share on revenue of $5.88 billion. The inclement weather has negatively impacted the North American operations. The management believes the softness in the demand for completion services in the North American market will improve in the coming months. In addition, the company will be hurt by the continuing capacity squeeze in the Permian Basin.
International Business Machines Corp. (IBM) is set to post fourth-quarter results on Tuesday after the bell. Analysts expect earnings to fall 5.80% to $4.84 per share as lesser deals signed could hurt most of the revenue of the segments. Revenue is anticipated to decline by 3.50% to $21.75 billion. The top line is likely to be hurt by lower solutions software and transaction processing software sales.
Capital One Financial (COF) will post Q4 results on Tuesday. Analysts project the company to report earnings of $2.38 per share on revenue of $7.08 billion. The results will be benefited by lower provision for credit losses and a fall in income tax provision. The top line is likely to be hurt by lower non-interest income and a minor increase in net interest income.
Consumer goods giant Procter & Gamble (PG) will announce Q2 earnings on Wednesday before the bell. Earnings are expected to rise by 1.70% to $1.21 per share and revenue is likely to decline by 1.50% to $17.14 billion. The top line is likely to be hurt by a decline in other major segments despite higher demand for beauty products. The bottom line could be benefited from the gains due to the dissolution of the PGT Healthcare partnership and a lower tax rate.
United Technologies Corp. (UTX) is set to post fourth-quarter results on Wednesday. Analysts project earnings to fall 4.40% to $1.53 per share due to the decision to split into three companies. Revenue is predicted to rise by 7.60% to $16.88 billion helped by organic sales growth, the absence of a nonrecurring charge incurred at Pratt & Whitney in the previous year quarter and foreign exchange headwind. The spin-off is beneficial in the top line while dilution could lower the adjusted earnings.
Comcast Corporation (CMCSA) will report Q4 earnings on Wednesday. Analysts see a profit of $0.62 per share on revenue of $27.57 billion. The top line is likely to be driven by increases in high-speed internet, higher distribution, theatrical, content licensing, and advertising revenue. The results will be benefited by the customer relationship growth accelerated on higher broadband net additions.
Ford Motor Company (F) could post Q4 results on Wednesday after the bell. Earnings are anticipated to drop by 17.90% to $0.32 per share and revenue is likely to decline by 3.90% to $37.01 billion. The results will be impacted by the continued challenges in the Europe and China market. Also, the company could be hurt by the major restructuring plan of its European operations including job cuts, factory closures and production stoppage for certain models.
Texas Instruments (TXN) will report Q4 earnings on Wednesday. Analysts see a profit of $1.24 per share on revenue of $3.75 billion. The results will be benefited by the management of costs and expenses as well as lower income taxes provision. The top line is likely to be hurt by the slower demand for its products across most markets.
As American Airlines Group Inc. (AAL) announces Q4 results on Thursday before the bell, analysts expect earnings of $1.04 per share on revenue of $10.98 billion. The bottom line is likely to be impacted by an increase in aircraft fuel price and higher operating expenses. Strong demand for air travel continues to favor the top line.
America’s largest low-cost carrier, Southwest Airlines (LUV), is set to post fourth-quarter results on Thursday. Analysts expect earnings to jump 39% to $1.07 per share as it continues investing in and deploying new operations, technology, and airport infrastructure to support future growth. Revenue is anticipated to rise by 7.50% to $5.67 billion despite being weighed down by the rising fuel prices.
Semiconductor giant Intel (INTC) will post fourth-quarter results on Thursday after the bell. Analysts project the company to report earnings of $1.22 per share on revenue of $19.01 billion. The results will be driven by the strength across businesses and strong customer demand for Intel platforms. The company is likely to achieve revenue growth in every business segment. Data-centric and PC-centric businesses could remain the highlight among investors.
Coffee giant Starbucks (SBUX) will report first-quarter results on Thursday. Analysts predict earnings of $0.65 per share on revenue of $6.49 billion. The results could be hurt by the rising competition in the caffeinated beverage market. Also, concerns have been rising that the unique branding strategy and premium products are losing the appeal. Starbucks has been seeing a dip in customer traffic to its coffee shops and for regaining traffic, the company has been simplifying its business operations and adopting new strategies.
AbbVie Inc. (ABBV) will announce Q4 earnings on Friday before the bell. Earnings are expected to jump by 30.40% to $1.93 per share and revenue is likely to increase by 8.10% to $8.37 billion. The results will be benefited from the sales growth from Humira, Imbruvica, and HCV. The R&D expenses are likely to rise for the quarter due to more combinations are on road to the market.
As Colgate-Palmolive (CL) announces Q4 results on Friday, analysts expect earnings of $0.73 per share on revenue of $3.78 billion. The results could be a challenging one with category growth rates remaining soft in many markets and unfavorable movements in foreign exchange. Market volatility in Brazil and trade inventory reductions in China could hurt the top line.
Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing a slowdown in North American sales. Meanwhile, earnings
Goldman Sachs (GS) exceeded analysts’ expectations, as investment banking revenue surged nearly 90%. Goldman market research report covers key aspects about the firm including company profile, financial highlights and key